Stay up-to-date with the latest developments in securities law through access to both news and all statutes and regulations. Find relevant corporate filings through a searchable EDGAR database. And...
Allergan Inc. has reached a $15 million settlement with the Securities and Exchange Commission to resolve claims that it failed to make appropriate disclosures during merger talks, the agency announced Jan. 17 ( In re Allergan, Inc. , S.E.C., No. Admin. Proc. File No. 3-17790, 1/17/17 ).
The drugmaker didn’t reveal talks with “potentially friendlier merger partners” in a timely manner after a tender offer from Valeant Pharmaceuticals International Inc. and co-bidders in June 2014, according to the SEC. Allergan ultimately entered merger discussions with Actavis plc, which acquired it.
“Allergan failed to fully and timely disclose information about potential merger transactions it was negotiating behind the scenes in response to the Valeant bid,” Andrew M. Calamari, director of the SEC’s New York Regional Office, said in a statement. “As outlined in our order, Allergan was slow to act even after SEC staff reminded the company about its disclosure obligations.”
“Allergan’s wholly owned subsidiary, Allergan Inc., has consented to the issuance of an administrative cease-and-desist order by the Securities and Exchange Commission, in final settlement of a previously disclosed SEC investigation,” Mark Marmur, a spokesman for the company, said in a statement to Bloomberg. “The SEC’s order does not make any finding of intentional wrongdoing, and does not include any charges against Allergan Plc.”
To contact the reporter on this story: Andrew Ramonas in Washington at firstname.lastname@example.org
To view this order, visit https://www.sec.gov/litigation/admin/2017/34-79814.pdf.
Copyright © 2017 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)